Characteristics of Sexual Dysfunction in Patients With Lung Cancer
NCT ID: NCT06018376
Last Updated: 2024-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
553 participants
OBSERVATIONAL
2023-07-13
2024-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The results of this research will make it possible to carry out interventions specifically directed at this population and to modify the oncological follow-up guidelines currently in force. Likewise, the information collected will serve as the basis for generating new protocols for a multidisciplinary approach, including the participation of psychology and specialists in urology, gynecology, and psychiatry.
The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational Study Group
* Age greater than or equal to 18 years and less than or equal to 70 years.
* Diagnosis of lung cancer stages IB to IV.
* Having received systemic oncological treatment for at least 3 months
* ECOG ≤ 2
Systemic oncological treatment
Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Systemic oncological treatment
Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of lung cancer stages IB to IV.
* Having received systemic oncological treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months with stable tumor disease or partial or complete response in images.
* ECOG ≤ 2
Exclusion Criteria
* Individuals with physical disability or cognitive impairment that prevents them from completing the electronic data collection form.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación GECP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aylen Vanessa Ospina Serrano, MD
Role: STUDY_CHAIR
Hospital Puerta del Hierro Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Alexander Flemming
Buenos Aires, , Argentina
Oncomedica, IMAT
Montería, Monteria, Colombia
Clínica Universitaria Colombia
Bogotá, , Colombia
Clinica del Occidente
Cali, , Colombia
Hematooncologos SA
Cali, , Colombia
Clínica de Medellín
Medellín, , Colombia
ALIADAS Instituto Nacional de Enfermedades Neoplasicas
Surquillo, , Peru
Centro Hospitalar do Porto
Porto, , Portugal
Hospital General de Elche
Elche, Alicante, Spain
ICO Badalona, Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital General de Granollers
Granollers, Barcelona, Spain
Hospital La Mancha Centro
Alcázar de San Juan, Ciudad Real, Spain
Hospitalario Universitario A Coruña
A Coruña, La Coruña, Spain
Hospital de Fuenlabrada
Fuenlabrada, Madrid, Spain
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain
Hospital Infanta Sofia
San Sebastián de los Reyes, Madrid, Spain
Hospital Universitario Cruces
Barakaldo, Vizcaya, Spain
Hospital Universitari Vall d' Hebron
Barcelona, , Spain
Hospital General Universitario de Ciudad Real
Ciudad Real, , Spain
Hospital Universitario Lucus Augusti
Lugo, , Spain
Hospital Clínico San Carlos
Madrid, , Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, , Spain
Hospital Universitari Son Llatzer
Palma de Mallorca, , Spain
Hospital Clínico de Salamanca
Salamanca, , Spain
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife, , Spain
Xarxa sanitaria Santa Tecla- Tarragona
Tarragona, , Spain
Hospital General Universitario de Valencia
Valencia, , Spain
Hospital Universitario La Fe
Valencia, , Spain
Hospital Clínico Universitario de Valladolid
Valladolid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ospina-Serrano AV, Maximiano C, Cantos B, Torrente M, Mendez M, Sanchez JC, Calvo V, Collazo-Lorduy A, Blanco M, Nunez B, Triana I, Parejo C, Martinez P, Duma N, Provencio-Pulla M. Sexual dysfunction in patients with cancer, a challenge in oncology practice: results of the CLARIFY project. Clin Transl Oncol. 2024 May;26(5):1147-1156. doi: 10.1007/s12094-023-03332-0. Epub 2023 Nov 2.
Related Links
Access external resources that provide additional context or updates about the study.
Web page of the sponsor where users can find more information about Fundación GECP studies
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GECP 23/01_LUDICAS
Identifier Type: -
Identifier Source: org_study_id